Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Narrative) (Details)

v3.4.0.3
Notes Payable (Narrative) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Apr. 07, 2016
May. 31, 2015
May. 15, 2015
Jul. 31, 2012
Debt Instrument [Line Items]              
Compounded interest on notes payable $ 824,952            
Notes payable 60,900,000            
Change in fair value of financial instruments 1,125,359 $ 1,727,103          
Lymphoseek sales revenue 3,782,680 1,835,422 $ 10,300,000        
Notes payable, current 50,179,537   333,333        
Interest expense 2,200,000 967,000          
Interest expense recorded related to amortization 72,875 212,813          
R-NAV [Member]              
Debt Instrument [Line Items]              
Notes payable, current 333,333            
Platinum Credit Facility [Member]              
Debt Instrument [Line Items]              
Maximum borrowing capacity, amount             $ 50,000,000
Current borrowing capacity             $ 35,000,000
Compounded interest on notes payable 306,000            
Notes payable 8,800,000            
Remaining borrowing capacity 27,300,000            
Unused additional borrowing capacity 15,000,000            
Platinum notes payable 1,900,000            
Change in fair value of financial instruments (1,100,000) $ (1,700,000)          
Estimated fair value 10,700,000            
Capital Royalty Partners II LP [Member]              
Debt Instrument [Line Items]              
Compounded interest on notes payable 519,000            
Notes payable $ 51,800,000            
Debt instrument face amount         $ 50,000,000    
Debt Instrument, unused borrowing capacity         $ 10,000,000    
Payment terms 2 years            
Debt discount related to lender fees and other costs           $ 2,200,000  
Notes payable, discounts $ 2,000,000            
End-of-term fee amount 1,000,000         1,000,000  
EBITDA, less than 5,000,000            
Minimum sales revenue target $ 22,500,000   11,000,000        
Minimum sales revenue target in 2020           45,000,000  
Cure right ratio 2.50%            
Liquidity minimum $ 5,000,000         $ 5,000,000  
Debt instrument default interest rate percentage 18.00%            
Reduced minimum sales revenue target in 2015     $ 10,000,000        
Capital Royalty Partners II LP [Member] | Subsequent Event [Member]              
Debt Instrument [Line Items]              
Debt instrument default interest rate percentage       18.00%